Diabetes Mellitus: Epidemiology, Pathophysiology & Management

Diabetes Mellitus

Comprehensive Overview: Epidemiology, Etiology, Pathophysiology, and Management

Global Epidemiology

The global prevalence of diabetes is surging rapidly. In 2021, approximately 537 million adults were affected. Projections estimate this number will rise to 643 million by 2030 and 783 million by 2045. Low- and middle-income countries currently host ~80% of these cases.

Introduction to Diabetes Mellitus

Diabetes mellitus is a chronic metabolic disorder defined by hyperglycemia caused by defects in insulin secretion, action, or both. It leads to long-term organ damage. <br><br><b>Key Classifications:</b><br>• <b>Type 1:</b> Autoimmune beta-cell destruction.<br>• <b>Type 2:</b> Insulin resistance and relative deficiency (~96% of cases).

Etiology & Risk Factors

Genetic Predisposition: Family history significantly increases risk.

Obesity & BMI: High Body Mass Index is the leading driver, contributing to over half of T2D disability burden.

Lifestyle Factors: Sedentary behavior and unhealthy diets high in processed foods.

Demographic Shifts: Aging populations and rapid urbanization, especially in low/middle-income countries.

Pathophysiology

<b>Insulin Resistance:</b> Peripheral tissues (muscle, fat, liver) fail to respond adequately to insulin, impeding glucose uptake.<br><br><b>Beta-Cell Dysfunction:</b> The pancreas cannot secrete enough insulin to overcome this resistance.<br><br><b>Metabolic Syndrome:</b> Chronic high glucose damages blood vessels and nerves, leading to cardiovascular disease and nephropathy.

Clinical Manifestations

Classic Symptoms: Polyuria (excessive urination), Polydipsia (excessive thirst), and Polyphagia (excessive hunger).

Physical Signs: Unexplained weight loss, chronic fatigue, and blurred vision.

Acute Complications: Diabetic Ketoacidosis (Type 1) or Hyperosmolar Hyperglycemic State (Type 2).

Chronic Issues: Microvascular (retinopathy, neuropathy) and Macrovascular (stroke, heart disease).

Diagnosis Criteria

Diagnosis relies on standardized laboratory criteria to ensure accuracy:<br><br><b>1. Fasting Plasma Glucose:</b> ≥126 mg/dL<br><br><b>2. Oral Glucose Tolerance Test (2-hour):</b> ≥200 mg/dL<br><br><b>3. Hemoglobin A1C:</b> ≥6.5%<br><br><b>4. Random Glucose:</b> ≥200 mg/dL (in presence of symptoms)<br><br><i>Results should be confirmed by repeat testing in the absence of unequivocal hyperglycemia.</i>

Non-Pharmacological Management

Lifestyle modification is the cornerstone of management:<br><br><b>Medical Nutrition Therapy:</b> Balanced, low-calorie diets tailored to individual needs.<br><br><b>Physical Activity:</b> Minimum of 150 minutes/week of moderate exercise.<br><br><b>Weight Management:</b> Achieving 5-10% weight loss significantly reduces A1C.<br><br><b>Monitoring:</b> Use of digital tools and continuous glucose monitors (CGM) to aid adherence.

Pharmacological Management

First-Line Therapy (T2D): Metformin remains the foundational medication.

GLP-1 Receptor Agonists: (e.g., semaglutide) Added for weight loss benefits and cardioprotection.

SGLT2 Inhibitors: (e.g., empagliflozin) Prescribed for heart and kidney protection benefits.

Insulin Therapy: Essential for Type 1 Diabetes and advanced Type 2 Diabetes when oral agents are insufficient.

Nearly 45% of diabetes cases remain undiagnosed globally. Early screening and access to care are critical to stopping the silent progression of this disease.

Global Public Health Observation